– Completed Initial Public Offering (IPO) of common stock, raising gross proceeds of $82.1M
– Single Ascending Dose (SAD) portion of Phase 1 study of CMP-CPS-001 completed; safety data anticipated in Q1 2025
– Entered strategic research collaboration with BioMarin valued at over $370M
GlobeNewswire,is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Latest posts by GlobeNewswire (see all)
- ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Zynex, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ZYXI - April 20, 2025
- Writer/painter-turned cultural heritage preserver behind Spring Festival’s UNESCO heritage status success - April 20, 2025
- Boston Hemp Launches New Line of Premium THCa Concentrates - April 20, 2025
